Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma

Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melasma Hyperpigmentation Melanosis Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

PakEmiratesMH

Rawalpindi, Punjab Province, Pakistan

About this study

A comparative study to evaluate Efficacy and tolerability of new lotion in the treatment of Melasma.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age between 18-50
No systemic therapy
All Co-morbids

Exclusion criteria

Pregnancy
Age >50
Taking oral treatment for melasma

Treatment and study plan

Metformin and Nicotinamide vs Kligman Formula

Drug

Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Primary outcomes

Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Time frame: 12 weeks

Efficacy with measurement of MASI score 4 weeks apart

Sponsors and collaborators

Lead sponsor

Ishtiaq Ahmed

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Mar 30, 2023
Registry last updated: May 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed